Citations

Clear

3042 citation(s) found for "Kumar, S".

Radiation arteritis following treatment for Wilms’ tumor: an unusual case of weight loss
Ghosh, Amit Kumar , Lundstrom, Carl E, Edwards, William D.

Mayo Clinic

Vascular Medicine | October 11, 2002 | Volume: 7 | Issue: 1 | Pages: 19-23

10.1191/1358863x02vm408cr | PMID 12083729 Get It

Wilms’ tumor is the most common pediatric primary renal cancer and is highly responsive to surgery and chemotherapy. The role of radiotherapy has evolved in the last three decades from the use of stepwise incremental doses in all patients to the current concept of added radiotherapy in advanced cases or in those with unfavorable pathology. To the authors’ knowledge, this is the first case of a young woman with prior history of Wilms’ tumor and significant weight loss due to radiation arteritis involving the abdominal vasculature. A 31-year-old woman presented with a history of weight loss and severe malnutrition. An angiogram revealed that the aorta was occluded below the renal artery. The celiac artery and the superior mesenteric artery were occluded at the origin, and large intercostal collaterals reconstituted the pelvic circulation. She was initially treated with total parenteral nutrition (TPN) and underwent an infrarenal aortic bypass surgery. Histopathology of the aorta revealed intimal fibrocalcific thickening and changes consistent with radiation-induced arteritis. Later, she was readmitted with progressive hepatic insufficiency. Despite intensive medical therapy, she died of multi-organ failure.
Convertases other than furin cleave β‐secretase to its mature form
Pinnix, Inga, Roseberry, Beverly, Onstead, Luisa, Mallender, William D. , Sucic, Joseph F., Roseberry, Beverly J., Sambamurti, Kumar

Mayo Clinic

The FASEB Journal | July 26, 2002 | Volume: 15 | Issue: 10 | Pages: 1810-1812

10.1096/fj.00-0891fje | PMID 11481238 Get It

ABSTRACT An aspartyl protease, Beta‐Site APP cleaving enzyme (BACE), was identified as the β‐secretase responsible for generating the Amyloid β protein that is believed to cause Alzheimer's disease. BACE has a short propeptide domain that is absent in the mature enzyme because of proteolytic cleavage after the sequence RLPR. This sequence is a predicted substrate for proprotein convertases such as furin. To determine the role of furin and other proprotein convertases, we expressed proBACE in a furin‐deficient mutant Chinese hamster ovary (CHO‐K1) line, RPE.40. ProBACE signal was higher in RPE.40 than in the CHO‐K1 parent, which confirmed that furin plays a role in propeptide removal. However, two independent approaches showed that proBACE is cleaved to mature BACE in RPE.40: proBACE was rapidly turned over in RPE.40 although total BACE was stable, and decanoyl‐RVKR‐chloromethylketone, an inhibitor of the proprotein convertase family, substantially increased proBACE levels in both RPE40 and CHO‐K1. Transient transfection shows that furin, PACE4, PC5/6, and PC7 mediate BACE cleavage in vivo , at least when overexpressed. RPE.40 is proficient in BACE activity despite its furin deficiency. Therefore, our finding that proBACE is cleaved in this mutant leaves open the possibility that maturation is an important regulatory step and a therapeutic target.
Reduction of Aβ accumulation in the Tg2576 animal model of Alzheimer's disease after oral administration of the phosphatidylinositol kinase inhibitor wortmannin
Haugabook, Sharie J., Le, Tien V., Yager, Debra, Zenk, B., Healy, Brent, Eckman, Elizabeth A. , Prada, Cristian-Mihail, Younkin, Linda H., Murphy, P. L., Pinnix, Inga, Onstead, Luisa, Golde, Todd E. , Younkin, Steven G. , Eckman, Christopher B., Sambamurti, Kumar , Dickson, Dennis W.

Mayo Clinic

The FASEB Journal | July 26, 2002 | Volume: 15 | Issue: 1 | Pages: 16-18

10.1096/fj.00-0528fje | PMID 11099491 Get It

ABSTRACT The abnormal accumulation of the amyloid β protein (Aβ) has been implicated as an early and critical event in the etiology and pathogenesis of Alzheimer's disease (AD). Compounds that reduce Aβ accumulation may therefore be useful therapeutically. In cell‐based screens we detected a significant reduction in Aβ concentration after treatment with the phosphatidylinositol kinase inhibitors wortmannin and LY294002. To determine the effect of this class of compounds on in vivo Aβ accumulation, we administered wortmannin to the Tg2576 mouse model of AD. Oral administration of wortmannin over four months resulted in a significant, non‐overlapping 40%–50% reduction in the number of senile plaques, one of the pathological hallmarks of AD. Sandwich ELISA analysis of formic acid extractable Aβ in the brain of treated animals indicates that both Aβ40 and the longer, more amyloidogenic form of the peptide, Aβ42, were significantly reduced. These data provide the first direct evidence that compounds identified by their ability to reduce Aβ concentration in vitro can reduce Aβ accumulation and deposition in the brain, thus establishing a basic paradigm for the identification and evaluation of additional compounds that lower Aβ accumulation.
Cell‐free assays for γ‐secretase activity
McLendon, Chris, Xin, Tianpei A., Ziani‐Cherif, Chewki , Murphy, M. Paul, Findlay, Kirk A., Lewis, Patrick A. , Pinnix, Inga, Fauq, Abdul H. , Golde, Todd E. , Sambamurti, Kumar , Wang, Rong

Mayo Clinic

The FASEB Journal | July 26, 2002 | Volume: 14 | Issue: 15 | Pages: 2383-2386

10.1096/fj.00-0286fje | PMID 11024004 Get It

ABSTRACT The amyloid β‐protein (Aβ) deposited in Alzheimer's disease (AD) is a normally secreted proteolytic product of the amyloid β‐protein precursor (APP). Generation of Aβ from the APP requires two sequential proteolytic events: an initial β‐secretase cleavage at the amino terminus of the Aβ sequence followed by γ ‐secretase cleavage at the carboxyl terminus of Aβ. We describe the development of a robust in vitro assay for γ ‐secretase cleavage by showing de novo Aβ production in vitro and establish that this assay monitors authentic gamma‐secretase activity by documenting the production of a cognate γ ‐CTF, confirming the size of the Aβ produced by mass spectrometry, and inhibiting cleavage in this system with multiple inhibitors that alter γ‐ secretase activity in living cells. Using this assay, we demonstrate that the γ‐secretase activity 1 ) is tightly associated with the membrane, 2 ) can be solubilized, 3 ) has a pH optimum of 6.8 but is active from pH 6.0 to pH >8.4, and 4 ) ascertain that activities of the γ ‐40 and γ ‐42 are indeed pharmacologically distinct. These studies should facilitate the purification of the protease or proteases that are responsible for this unusual activity, which is a major therapeutic target for the treatment of AD.
Dendritic cell modulation by 1α,25 dihydroxyvitamin D 3 and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro
Griffin, Matthew D. , Lütz, W, Phan, Vy, Bachman, Lori A. , McKean, D J, Kumar, Rajiv , Griffin, Matthew D , Kumar, Rajiv

Mayo Clinic

Proceedings of the National Academy of Sciences | July 26, 2002 | Volume: 98 | Issue: 12 | Pages: 6800-6805

10.1073/pnas.121172198 | PMID 11371626 Get It

Dendritic cells (DCs) play a central role in regulating immune activation and responses to self. DC maturation is central to the outcome of antigen presentation to T cells. Maturation of DCs is inhibited by physiological levels of 1α,25 dihydroxyvitamin D 3 [1α,25(OH) 2 D 3 ] and a related analog, 1α,25(OH) 2 -16-ene-23-yne-26,27-hexafluoro-19-nor-vitamin D 3 (D 3 analog). Conditioning of bone marrow cultures with 10 −10 M D 3 analog resulted in accumulation of immature DCs with reduced IL-12 secretion and without induction of transforming growth factor β1. These DCs retained an immature phenotype after withdrawal of D 3 analog and exhibited blunted responses to maturing stimuli (CD40 ligation, macrophage products, or lipopolysaccharide). Resistance to maturation depended on the presence of the 1α,25(OH) 2 D 3 receptor (VDR). In an in vivo model of DC-mediated antigen-specific sensitization, D 3 analog-conditioned DCs failed to sensitize and, instead, promoted prolonged survival of subsequent skin grafts expressing the same antigen. To investigate the physiologic significance of 1α,25(OH) 2 D 3 /VDR-mediated modulation of DC maturity we analyzed DC populations from mice lacking VDR. Compared with wild-type animals, VDR-deficient mice had hypertrophy of subcutaneous lymph nodes and an increase in mature DCs in lymph nodes but not spleen. We conclude that 1α,25(OH) 2 D 3 /VDR mediates physiologically relevant inhibition of DC maturity that is resistant to maturational stimuli and modulates antigen-specific immune responses in vivo .
Phenserine regulates translation of β-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development
Shaw, Karen T. Y., Utsuki, Tadanobu, Rogers, Jack T. , Yu, Qian‐sheng, Sambamurti, Kumar , Brossi, Arnold, Ge, Yuan‐Wen, Lahiri, Debomoy K. , Greig, Nigel H.

Mayo Clinic

Proceedings of the National Academy of Sciences | July 26, 2002 | Volume: 98 | Issue: 13 | Pages: 7605-7610

10.1073/pnas.131152998 | PMID 11404470 Get It

The reduction in levels of the potentially toxic amyloid-β peptide (Aβ) has emerged as one of the most important therapeutic goals in Alzheimer's disease. Key targets for this goal are factors that affect the expression and processing of the Aβ precursor protein (βAPP). Earlier reports from our laboratory have shown that a novel cholinesterase inhibitor, phenserine, reduces βAPP levels in vivo . Herein, we studied the mechanism of phenserine's actions to define the regulatory elements in βAPP processing. Phenserine treatment resulted in decreased secretion of soluble βAPP and Aβ into the conditioned media of human neuroblastoma cells without cellular toxicity. The regulation of βAPP protein expression by phenserine was posttranscriptional as it suppressed βAPP protein expression without altering βAPP mRNA levels. However, phenserine's action was neither mediated through classical receptor signaling pathways, involving extracellular signal-regulated kinase or phosphatidylinositol 3-kinase activation, nor was it associated with the anticholinesterase activity of the drug. Furthermore, phenserine reduced expression of a chloramphenicol acetyltransferase reporter fused to the 5′-mRNA leader sequence of βAPP without altering expression of a control chloramphenicol acetyltransferase reporter. These studies suggest that phenserine reduces Aβ levels by regulating βAPP translation via the recently described iron regulatory element in the 5′-untranslated region of βAPP mRNA, which has been shown previously to be up-regulated in the presence of interleukin-1. This study identifies an approach for the regulation of βAPP expression that can result in a substantial reduction in the level of Aβ.
Identification of 1α,25-Dihydroxyvitamin D3Response Elements in the Human Transforming Growth Factor β2 Gene
Wu, Yanhong , Craig, Theodore A., Lütz, W, Kumar, Rajiv , Kumar, Rajiv

Mayo Clinic

Biochemistry | July 26, 2002 | Volume: 38 | Issue: 9 | Pages: 2654-2660

10.1021/bi981944s | PMID 10052935 Get It

An AP-1 Site in the Nerve Growth Factor Promoter Is Essential for 1,25-Dihydroxyvitamin D3-Mediated Nerve Growth Factor Expression in Osteoblasts
Veenstra, Timothy D. , Fahnestock, Margaret , Kumar, Rajiv , Kumar, Rajiv

Mayo Clinic

Biochemistry | July 26, 2002 | Volume: 37 | Issue: 17 | Pages: 5988-5994

10.1021/bi972965+ | PMID 9558335 Get It

Zinc Binding Properties of the DNA Binding Domain of the 1,25-Dihydroxyvitamin D3 Receptor
Craig, Theodore A., Veenstra, Timothy D. , Naylor, Stephen , Tomlinson, Andy J., Johnson, Kenneth L. , Juranić, Nenad, Kumar, Rajiv , Macura, Slobodan , Kumar, Rajiv

Mayo Clinic

Biochemistry | July 26, 2002 | Volume: 36 | Issue: 34 | Pages: 10482-10491

10.1021/bi970561b | PMID 9265628 Get It

Determination of Calcium-Binding Sites in Rat Brain Calbindin D28K by Electrospray Ionization Mass Spectrometry
Veenstra, Timothy D. , Johnson, Kenneth L. , Tomlinson, Andy J., Naylor, Stephen , Kumar, Rajiv , Kumar, Rajiv

Mayo Clinic

Biochemistry | July 26, 2002 | Volume: 36 | Issue: 12 | Pages: 3535-3542

10.1021/bi9628329 | PMID 9132004 Get It